Minnesota legislators introduce what could possibly become the first law to curtail payers' rights to determine which biologics patients have access to.
Legislators in Minnesota have introduced a bill that would broaden access to biosimilars by requiring health plans and pharmacy benefit managers (PBMs) to cover all versions of biological agents, including biosimilars. The bill is a response to payer policies that sometimes narrow choices of biosimilars and reference products and may force providers and patients to use agents that are more costly than other versions of the same biologics.
“The change would give all patients access to the most affordable and effective version of their medication without compromising safety standards,” Representative Jennifer Schultz (D, Duluth) and Senator Carla Nelson (R, Rochester) said in a statement announcing the bill (SF 990). Schultz said the draft legislation was developed in consultation with research scientists at Essentia Health and Mayo Clinic.
“Biosimilar medications are just as safe and effective as their brand counterparts,” said Eric Tichy, vice chair of Mayo Clinic Pharmacy Supply Solutions. “They are also the most powerful tool we have to control the cost of prescription drugs. Facilitating provider prescribing of biosimilar products for patients supports high-quality care and reduces delays and red tape while also managing the high costs of medication."
According to the language of the bill, PBMs and health plans would not be permitted to prefer or require the use of reference biologics, biosimilars to reference products, or biologics deemed “interchangeable” to reference biologics. If a PBM or health carrier offers coverage of a reference product or biosimilar, it must also cover all versions of that same drug, including reference and biosimilars.
Also under the bill, the Minnesota commissioner of health would be required to track the legislation’s effect on net prices for different payers of biological products, interchangeable biological products, and biosimilar products.
JD Supra, the legal news website, stated that the bill if enacted would produce the first law of this kind. The bill’s supporters have chosen January 1, 2022 as the proposed go-live date.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.